Clinical trials: Diabetic Macular Edema (DME)
Cystoid Macular Edema, Diabetic Macular Edema
Variable Interval Versus Set Interval Aflibercept for DME
The purpose of this study is to compare the safety and efficacy of intravitreal Eylea injections at a set interval, versus a variable dosing schedule (likely longer than one month), based on a specific individual's disease…
- Trial name
- EVADE (NCT02392364)
- Testing
- Intravitreal Aflibercept Injection
- Where
- 2 sites in United States
- Volunteers
- 50 people
- Sponsor
- California Retina Consultants
Diabetic Macular Edema
Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema
This study was designed to confirm the efficacy and safety of ranibizumab (0.5 mg) as adjunctive therapy when added to laser photocoagulation and/or as monotherapy in Asian patients with visual impairment due to Diabetic Macular…
- Trial name
- REVEAL (NCT00989989)
- Testing
- Ranibizumab, Laser photocoagulation
- Where
- 35 sites in China, Hong Kong and 4 more
- Volunteers
- 396 people
- Sponsor
- Novartis
Diabetic Macular Edema
A Clinical Study Evaluating the Safety, Tolerability and Initial Efficacy of SKG0106 Intravitreal Injection in Diabetic Macular Edema (DME) Patients
This is a clinical study to evaluate the safety, tolerability and initial efficacy of SKG0106 intravitreal injection in diabetic macular edema (DME) patients.
- Trial name
- NCT06237777
- Testing
- SKG0106 intravitreal injection dose level 1, 2 or 3
- Where
- 2 sites in China
- Volunteers
- 3 people
- Sponsor
- Wang Min
Diabetic Macular Edema
Ranibizumab "Treat and Extend" in Diabetic Macular Edma
This study is designed to explore a more individualized treatment regime based on achievement of disease stability to define a personal optimal treatment interval with ranibizumab in patients with visual impairment due to…
- Trial name
- OPTIMAL (NCT01297569)
- Testing
- Ranibizumab
- Where
- Norway
- Volunteers
- 7 people
- Sponsor
- Novartis Pharmaceuticals
Diabetic Macular Edema, Retina Vein Occlusion
A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Diabetic Macular Edema and Retinal Vein Occlusion
Phase 2a multicenter, open-label, parallel-arm design study to evaluate the safety, tolerability and pharmacodynamics of a single intravitreal injection comparing 2 dose levels of GB-102 on subjects with Diabetic Macular Edema…
- Trial name
- NCT04085341
- Testing
- GB-102
- Where
- 6 sites in United States
- Volunteers
- 21 people
- Sponsor
- Graybug Vision
Diabetic Macular Edema
Curcumin and Intravitreal Dexamethasone in Diabetic Macular Edema
The aim of the study is to explore the effect of a curcumin formulation in combination to intravitreal dexamethasone therapy in patients with diabetic macular edema on morphological retinal characteristics and retreatment times.
- Trial name
- DIABEC (NCT03598205)
- Testing
- DIABEC plus intravitreal dexamethazone
- Where
- 3 sites in Italy
- Volunteers
- 72 people
- Sponsor
- Fondazione G.B. Bietti, IRCCS
Macular Edema Associated With Diabetes Mellitus
A Multi-Center Trial To Evaluate The Safety And Efficacy Of Pegaptanib Sodium(Macugen) Injected Into The Eye Every 6 Weeks For Up To 2 Years For Macular Swelling Associated With Diabetes, With An Open-Label Macugen Year Extension.
The purpose of the study is to test whether Macugen injected into the eye improves vision in more patients than the currently existing standard of care laser therapy.
- Trial name
- NCT00605280
- Testing
- Standard of Care, Macugen
- Where
- 73 sites in United States, Australia and 16 more
- Volunteers
- 317 people
- Sponsor
- Pfizer
Diabetic Macular Edema (DME)
Observational Study to Assess the Effect of Iluvien® in DME Patients Insufficiently Responsive to Available Therapies
This observational study aims to assess the safety and effect of Iluvien® in DME patients considered insufficiently responsive to available therapies in a real life setting in Germany.
- Trial name
- ILUMINATE (NCT02080091)
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- Alimera Sciences
Neovascular Age-related Macular Degeneration, Diabetic Macular Edema
VEGFA-targeting Gene Therapy to Treat Retinal and Choroidal Neovascularization Diseases
Patients who respond to anti-VEGF therapy but with refractory retinal and choroidal neovascularization diseases including neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME), and retinal vein…
- Conditions
- Neovascular Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- NCT05099094
- Testing
- BD311
- Where
- China
- Volunteers
- 3 people
- Sponsor
- Shanghai BDgene Co., Ltd.
Choroidal Neovascularization, Diabetic Retinopathy
PF-04523655 Dose Escalation Study, and Evaluation of PF-04523655 With/Without Ranibizumab in Diabetic Macular Edema (DME)
This is a two-part study. The first part (Stratum I) is an open-label, dose escalation, safety, tolerability and pharmacokinetic study, where active study drug (PF-04523655) will be given to all patients who participate.
- Conditions
- Choroidal Neovascularization, Diabetic Retinopathy, Diabetic Macular Edema
- Trial name
- MATISSE (NCT01445899)
- Testing
- PF-04523655 (Stratum I), ranibizumab, PF-04523655 (Stratum II)
- Where
- 51 sites in United States, Belgium and 5 more
- Volunteers
- 258 people
- Sponsor
- Quark Pharmaceuticals
Diabetic Macular Edema
A Study to Evaluate the Efficacy, Durability, and Safety of KSI-301 Compared to Aflibercept in Participants With Diabetic Macular Edema (DME)
This Phase 3 study will evaluate the efficacy, durability, and safety of KSI-301 compared to aflibercept in participants with treatment-naïve DME.
- Trial name
- GLIMMER (NCT04603937)
- Testing
- KSI-301, Aflibercept
- Where
- 72 sites in United States, Czechia and 6 more
- Volunteers
- 459 people
- Sponsor
- Kodiak Sciences Inc
Diabetic Macular Edema
Performance Assessment Tests in Working Individuals With DME Following Treatment With Ranibizumab
Performance assessment testing may be a useful tool to evaluate the impact of ranibizumab on day-to-day visual function in patients with Diabetic Macular Edema (DME).
- Trial name
- ERASER (NCT02107131)
- Testing
- Intravitreal ranibizumab 0.3mg
- Where
- 6 sites in United States
- Volunteers
- 40 people
- Sponsor
- California Retina Consultants
Age-Related Macular Degeneration
Treatment of Diabetic Macular Edema With 0.5mg Intraocular Ranibizumab (Lucentis)
In this prospective, open-label clinical study is to investigate the behavior of the retinal functions during development of diabetic macular disease (DME) under the influence of Lucentis.
- Trial name
- NCT01638858
- Testing
- Lucentis (Ranibizumab)
- Where
- Germany
- Volunteers
- 25 people
- Sponsor
- University of Luebeck
Diabetic Macular Edema, Retinal Disease
Assess the Efficacy and Safety of Repeat Intravitreal Injections of Foselutoclax (UBX1325) in Patients With DME (ASPIRE)
The goal of this clinical trial is to assess the efficacy and safety of multiple doses of foselutoclax (UBX1325) in patients with Diabetic Macular Edema.
- Conditions
- Diabetic Macular Edema, Retinal Disease, Macular Edema, Diabetes Mellitus
- Trial name
- NCT06011798
- Testing
- Aflibercept, foselutoclax
- Where
- 19 sites in United States
- Volunteers
- 52 people
- Sponsor
- Unity Biotechnology, Inc.
Diabetic Macular Oedema
A Study to Evaluate the Efficacy and Safety of IBI302 inSubjects With Diabetic Macular Edema（DME）
The study is designed for multi-center,randomized,double-masked,active-contralledstudy to evaluate effective and security of intravitrealinjection of IBI302 in subjects with Diabetic Macular Oedema.
- Trial name
- NCT06908876
- Testing
- IBI302, Faricimab
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Innovent Biologics Technology Limited (Shanghai R&D Center)
Diabetic Retinopathy, Macular Edema
A Study to Evaluate the Safety and Efficacy of THR-317 for the Treatment of Diabetic Macular Oedema (DME)
This study is conducted to evaluate the safety of THR-317 when administered intravitreally and to assess the compound's efficacy in improving best-corrected visual acuity (BCVA) and reducing central subfield thickness (CST) in…
- Trial name
- NCT03071068
- Testing
- Anti-PlGF recombinant monoclonal antibody, 4mg dose, Anti-PlGF recombinant monoclonal antibody, 8mg dose
- Where
- 13 sites in Czechia, Hungary and 1 more
- Volunteers
- 49 people
- Sponsor
- ThromboGenics
Efficacy, Safety
Effect of PPV+ILM Peeling +/- Subretinal Injection of Ringer Lactate in Management of Nontractional Refractory DME
To evaluate the efficacy and safety of combined pars plana vitrectomy and planned foveal detachment through subretinal injection of ringer's solution in patients with non-tractional refractory diabetic macular edema.
- Trial name
- NCT06271473
- Testing
- vitrectomy + ILM peeling +/- planned foveal detachment via subretinal injection of ringer's solution.
- Where
- 2 sites in Egypt
- Volunteers
- 20 people
- Sponsor
- Ain Shams University
Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME)
Study of JMKX003948 Ophthalmic Suspension in Healthy Participants
The study is a randomized, double-blind, placebo-controlled, phase 1 study of JMKX003948 Ophthalmic Suspension to evaluate the safety, tolerability and PK of single and multiple ascending doses in healthy participants.
- Trial name
- NCT06832657
- Testing
- JMKX003948 Ophthalmic Suspension
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Jemincare
Diabetic Macular Edema
Long-Term Efficacy & Safety of Aflibercept IVT for the Treatment of DME in Subjects Who Completed the VISTA-DME Trial
The Endurance Trial is a phase IV open label clinical study to assess the need for ongoing intravitreal aflibercept injections after the 3-year VISTA DME (VGFT-OD-1009; NCT01363440) end-point.
- Trial name
- NCT02299336
- Testing
- Aflibercept, Focal Laser
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Greater Houston Retina Research
Diabetic Macular Edema (DME)
High Dose Aflibercept in Diabetic Macular Edema in Patients With Previous Vitrectomy
Patients with diabetic macular edema (DME) sometimes must undergo vitrectomy surgery (PPV) for diabetic and non-diabetic related issues.
- Trial name
- NCT06662994
- Testing
- Aflibercept 8 mg (VEGF Trap-Eye, BAY86-5321)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Retina Consultants of Orange County